3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myeloid, Acute
150
Leukemia
67
Precursor Cell Lymphoblastic Leukemia-Lymphoma
28
Leukemia, Myelomonocytic, Acute
26
Leukemia, Monocytic, Acute
26
Myelodysplastic Syndromes
24
Leukemia, Erythroblastic, Acute
23
Leukemia, Megakaryoblastic, Acute
22
Congenital Abnormalities
21
Leukemia, Promyelocytic, Acute
13
Leukemia, Myelomonocytic, Chronic
12
Anemia, Refractory, with Excess of Blasts
12
Recurrence
8
Myeloproliferative Disorders
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma
7
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Eosinophilic, Acute
7
Leukemia, Biphenotypic, Acute
7
Leukemia, Basophilic, Acute
6
Carcinoma, Hepatocellular
6
Blast Crisis
6
Neoplasm, Residual
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Neutropenia
3
Neoplasms, Plasma Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Interventions
Doxorubicin
141
Ifosfamide
85
Radiotherapy
80
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
39
Etoposide
39
Docetaxel
39
Vincristine
37
Cisplatin
35
Trabectedin
32
Nivolumab
32
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Carboplatin
25
Temozolomide
23
Ipilimumab
22
Bevacizumab
20
Radiation
19
Surgical Procedures, Operative
18
Granulocyte Colony-Stimulating Factor
18
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Biopsy
17
eribulin
16
anlotinib
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma
×
Idarubicin
×
Clear all
NCT00876031
2022-11-08
CWS-2007-HR
University Hospital Tuebingen
Phase 3
Completed
195 enrolled